ADVITECH ANNOUNCES STOCK OPTION GRANTS
QUEBEC CITY, June 9, 2011 /CNW/ - Advitech Inc. ("Advitech" or the "Corporation") (TSXV: AVI) announces that it has granted today a total of 638,500 stock options to an officer.
Each stock option allows the holder thereof to acquire one common share of Advitech until June 9, 2016 for a price of $0.10 per share. The options are governed by the stock option plan of the Company and will vest in three instalments on the first, second and third anniversary of their date of grant.
Advitech, which includes its subsidiary Botaneco Specialty Ingredients Inc. since November 20, 2009, is a health sciences and technology company developing, manufacturing and marketing proprietary natural ingredients and formulations for oral and topical applications that have been clinically proven to be safe and effective for improving skin health and well being. The Corporation's products are based on three technological platforms which are: i) a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, ii) XP-828L for immune mediated inflammatory disorders, and iii) IM for anti-aging and wound healing. Advitech produces Hydresia®, a natural plant derived specialty ingredient which offers immediate moisturization advantages, formulating cost savings and excellent product aesthetics in a variety of product applications, Dermylex® for the treatment of mild-to-moderate psoriasis, and NudremylTM which acts on skin reconstruction, cellular regeneration and skin structure. More information is available and can be accessed at www.advitech.com and www.botaneco.ca.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information:
Michael Stangel, President and CEO